QuAC | CEHTRA

Are you dealing with Quaternary Ammonium Compounds?

We have a solution that will save you time, cost and resources !

Introducing

An umbrella interest group to cover all Quaternary Ammonium Compounds (QUATs) and PT Combinations

What is QuAC?

The active substances Didecyldimethylammonium chloride (DDAC – CAS 7173-51-5) and Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBAC/BKC – CAS 68424-85-1), used in biocidal products, are facing an important deadline. For products containing ADBAC/BKC, the submission deadline for BPR dossiers is July 1, 2025 for PT2. At CEHTRA, we have developed an innovative approach, successfully applied to DDAC dossiers, that helps companies meet these deadlines while saving time, resources, and costs.

QuAC Strategy

CEHTRA’s proposal is based on both: the companies’ main interests and our extensive experience dealing with Biocidal Product Family (BPR). With QuAC, you will have your own BPR dossiers, but also benefit from the synergies of a group.

BPR - Article 3(1)(s) specifies that a group of biocidal products having:

(a) Similar uses;

(b) The same active substances,

(d) Similar levels of risk and efficacy

Can be grouped in a Biocidal Product Family (BPF) BUT the latest guidance (CA-July19-Doc4.2-Final_rev2) introduces additional restrictions on similarity requirements that makes it more difficult to build a BPF, especially when trying to group products from different companies. The solution lies in simplifying and reducing differentiation in formulations.

On the other hand, companies prioritize endowing their products with specific performance characteristics that will make them stand out at market level.

At CEHTRA, we’ve designed a proposal with the legal support of Steptoe, that stands out from standard consortia and conventional approaches, offering you:

One-stop-shop - Cover all the Quats (Combinations between them, different PTs and Use)
Full control - You own your dossier and regulatory strategy
Flexibility - You take the lead, we adapt (no need to contract us for the full dossier)
Cost rationalization - A transparent and efficient approach
Confidentiality - No need to share sensitive information